Progress on Antiangiogenic Therapy for Patients with Malignant Glioma

Table 2

Selected clinical trials in patients with recurrent high grade glioma

Agent	Phase	Diagnosis	Number of patients and Histology	Response Rate	PFS-6
Bev + Ir [5, 77]	II	Recurrent MG	68 (33 AG, 35 GBM)		43% GBM, 59% AG
Bev versus Bev + Ir [6]	II	Recurrent GBM	85 GBM (Bev) Vs 82 GBM (Bev +Ir)	RRR = 28% (Bev), RRR = 37% (Bev +Ir)	42% (Bev) versus 50% (Bev + Ir)
Aflibercept [89]	II	Recurrent MG	48 (16 AG, 32 GBM)	50% AG30% GBM
Cediranib [90]	II	Recurrent GBM	16 GBM	56%
Vatalanib [91]	I/II	Recurrent GBM	55 GBM	PR = 4%, SD = 56%
XL184 [92]	II	Recurrent GBM	26 GBM	PR = 38%
Thalidomide [93]	II	Recurrent MG	39 (14 AG, 25 GBM)	PR = 6%, MR = 6%, SD = 33%
Cilengitide [94]	II	Recurrent GBM	81 GBM		16%

Abbreviations: Bev: bevacizumab, Ir: Irinotecan, PFS-6: progression free survival at 6 months, MG: malignant glioma, GBM: glioblastoma, AG: anaplastic glioma (includes anaplastic astrocytoma, anaplastic oligodendrogioma and anaplastic oligoastrocytoma), RR: response rate, RRR: radiological response rate, PR: partial response, SD: stable disease, MR: minor response, TMZ: temozolomide, and XRT: radiation.